SCHEMBL1662404

SCHEMBL1662404

CCOC(=O)C(C(=O)OCC)C1CN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.42
USP2 O75604 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
ALDH1A1 P00352 3/20 0.39
EPHX1 P07099 1/20 0.38
DPP4 P27487 1/20 0.38
NAMPT P43490 1/20 0.38
ADORA1 P30542 1/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
MAPT P10636 1/20 0.37
IDO1 P14902 1/20 0.37
RORC P51449 1/20 0.37
HPGD P15428 1/20 0.37
TSHR P16473 1/20 0.36
EED O75530 1/20 0.36
RBBP4 Q09028 1/20 0.36
SUZ12 Q15022 1/20 0.36
EZH2 Q15910 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL344169 0.90 EPHX1 (0.45) NR1H2L3MBTL1ALDH1A1EPHX1DPP4
SCHEMBL27887915 0.90 EPHX1 (0.45) NR1H2L3MBTL1ALDH1A1EPHX1DPP4
SCHEMBL1873727 0.86 EPHX1 (0.50) NR1H2L3MBTL1USP2SMN1; SMN2ALDH1A1
SCHEMBL19510734 0.83 GPR119 (0.44) NR1H2ALDH1A1DPP4MEN1KMT2A
SCHEMBL16423985 0.81 NR1H2 (0.46) NR1H2USP2SMN1; SMN2ALDH1A1DPP4
SCHEMBL18497663 0.81 NR1H2 (0.51) NR1H2USP2SMN1; SMN2ALDH1A1DPP4
SCHEMBL19074507 0.80 GPR119 (0.48) NR1H2L3MBTL1ALDH1A1EPHX1DPP4
SCHEMBL22655482 0.80 GPR119 (0.48) NR1H2L3MBTL1ALDH1A1EPHX1DPP4
SCHEMBL6105490 0.80 HPGD (0.46) USP2SMN1; SMN2ALDH1A1EPHX1DPP4
SCHEMBL6105487 0.80 HPGD (0.46) USP2SMN1; SMN2ALDH1A1EPHX1DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2306994-B1 S1P1 RECEPTOR AGONISTS AND USE THEREOF AMGEN INC (US) 2013-08-14 EP disclosed
US-20120129828-A1 S1P1 RECEPTOR AGONISTS AND USE THEREOF AMGEN INC. 2012-05-24 US disclosed
EP-2306994-A1 S1P1 RECEPTOR AGONISTS AND USE THEREOF Amgen, Inc (US) 2011-04-13 EP disclosed
US-7842685-B2 S1P1 receptor agonists and use thereof AMGEN INC. (US) 2010-11-30 US disclosed
US-20100029611-A1 S1P1 receptor agonists and use thereof AMGEN INC. (US) 2010-02-04 US disclosed
WO-2009154780-A1 S1P1 RECEPTOR AGONISTS AND USE THEREOF AMGEN INC. (US) 2009-12-23 WO disclosed
WO-2009154775-A1 S1P1 RECEPTOR AGONISTS AND USE THEREOF AMGEN INC. (US) 2009-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120129828-A1 S1P1 RECEPTOR AGONISTS AND USE THEREOF S1PR1, S1PR5, S1PR2 NR1H2 51/4885L3MBTL1 4137/4885USP2 4504/4885
US-20100029611-A1 S1P1 receptor agonists and use thereof S1PR1, S1PR5, S1PR2 NR1H2 51/4885L3MBTL1 4182/4885USP2 4518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.